Cutaneous toxicities in patients with metastatic uveal melanoma receiving tebentafusp: a retrospective review. The experience of a single large specialist institution.
{"title":"Cutaneous toxicities in patients with metastatic uveal melanoma receiving tebentafusp: a retrospective review. The experience of a single large specialist institution.","authors":"Xingyue Maria Wang, Andrew Furness, Kara Heelan","doi":"10.1093/ced/llaf426","DOIUrl":null,"url":null,"abstract":"<p><p>Tebentafusp is a novel T-cell receptor-bispecific protein that targets glycoprotein 100 and CD3. It is the only approved systemic therapy for patients with unresectable or metastatic HLA-A*02:01 positive uveal melanoma. Cutaneous toxicities are common, yet there are limited studies in the literature. We conducted a retrospective observational cohort study of patients with HLA-A*02:01- positive unresectable or metastatic uveal melanoma at our tertiary referral centre, who received tebentafusp therapy from August 2021 to January 2024. Cutaneous toxicity occurred in 89% of patients, but reactions were manageable with no patients permanently discontinuing treatment. To our knowledge, we also report the first case of bullous pemphigoid associated with tebentafusp.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ced/llaf426","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Tebentafusp is a novel T-cell receptor-bispecific protein that targets glycoprotein 100 and CD3. It is the only approved systemic therapy for patients with unresectable or metastatic HLA-A*02:01 positive uveal melanoma. Cutaneous toxicities are common, yet there are limited studies in the literature. We conducted a retrospective observational cohort study of patients with HLA-A*02:01- positive unresectable or metastatic uveal melanoma at our tertiary referral centre, who received tebentafusp therapy from August 2021 to January 2024. Cutaneous toxicity occurred in 89% of patients, but reactions were manageable with no patients permanently discontinuing treatment. To our knowledge, we also report the first case of bullous pemphigoid associated with tebentafusp.
期刊介绍:
Clinical and Experimental Dermatology (CED) is a unique provider of relevant and educational material for practising clinicians and dermatological researchers. We support continuing professional development (CPD) of dermatology specialists to advance the understanding, management and treatment of skin disease in order to improve patient outcomes.